Postoperative Pain Control in Femto-Lasik with the Use of Therapeutic Contact Lenses Soaked in Ketorolac Trometamol 0.45% TCL Soaked in Ketorolac for Pain After Femto-Lasik
Lorena Figueiredo Patricio1*, Renata Leite de Pinho Tavares2, Ramon Coral Ghanem2 and Vinícius Coral Ghanem3
1Fellow in Refractive Surgery at Sadalla Amin Ghanem Eye Hospital - Joinville/SC, Brazil
2Ophthalmologist at Sadalla Amin Ghanem Eye Hospital - Joinville/SC, Brazil
3Ophthalmologist and Medical Director at Sadalla Amin Ghanem Eye Hospital - Joinville/SC, Brazil
*Corresponding Author: Lorena Figueiredo Patricio, Fellow in Refractive Surgery at Sadalla Amin Ghanem Eye Hospital - Joinville/SC, Brazil.
February 27, 2023; Published: March 17, 2023
To compare the postoperative pain between patient eyes submitted to femtosecond laser-assisted LASIK after placement of contact lens (TCL) soaked in 0.45% ketorolac trometamol in one eye and placement of a TCL not soaked in the drug solution in the contralateral eye.
Setting: Sadalla Amin Ghanem Eye Hospital in Joinville, SC, Brazil.
Design: A double-blind, randomized, contralateral, prospective clinical study.
Methods: Patients submitted to LASIK with femtosecond laser received the TCL soaked in ketorolac trometamol 0.45% (Acular® CMC, Allergan, Inc., Irvine, CA) in one eye and a TCL without any medication in the other eye. The laterality selection was done randomly through a drawing. Patients with ocular surface diseases or those on chronic pain medication were excluded. The pain sensation was registered by the patients during 3 postoperative periods. The Wong-Baker Faces pain rating scale (from 0 to 10) was used.
Results: The study involved 64 eyes from 32 patients. The average postoperative pain score 3 hours after surgery in the eyes with TCL + ketorolac was 1.47 ± 2.12, significantly lower than the score among the eyes that received just the TCL, which was 3.31 ± 2.73 (P = 0.004). No statistically significant difference for pain level was observed 6 hours after surgery (P =0.053) and upon awakening the next day (P = 0.081).
Conclusion: The use of TCL soaked in ketorolac trometamol 0.45% safely provides significant pain reduction three hours after femto-LASIK when the pain is most intense.
Keywords: Pain; LASIK; Femtosecond Laser; Ketorolac; Contact Lenses
- Kim SJ., et al. “Nonsteroidal anti-inflammatory drugs in ophthalmology”. Survey on Ophthalmology2 (2010): 108-133.
- Acular LS. ® [package insert]. Irvine, CA: Allergan, Inc.; (1997).
- Donnenfeld ED., et al. “Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve”. Journal of Cataract and Refractive Surgery9 (2006): 1474-1482.
- Perry HD and Donnenfeld ED. “An update on the use of ophthalmic ketorolac tromethamine 0.4%”. Expert Opinion on Pharmacotherapy1 (2006): 99-107.
- Price FW Jr., et al. “Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double-masked, placebo-controlled trial”. Journal of Refractive Surgery2 (2002): 140-144.
- Price MO and Price FW. “Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery”. Current Medical Research and Opinion 12 (2004): 2015-2019.
- Sandoval HP., et al. “Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation”. Journal of Ocular Pharmacology and Therapeutics 4 (2006): 251-257.
- Solomon KD., et al. “Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in postphotorefractive keratectomy patients”. Journal of Cataract and Refractive Surgery8 (2004): 1653-1660.
- ® LS [package insert]. Irvine, CA: Allergan, Inc.; (2008).
- Attar M., et al. “Farmacocinética ocular de 0,45% de cetorolaco de trometamina”. Clinical Ophthalmology 4 (2010): 1403-1408.
- Shetty R., et al. “Pain management after photorefractive keratectomy”. Journal of Cataract and Refractive Surgery 7 (2019): 972-1076.
- Xu K., et al. “Ex vivo corneal epithelial wound healing following exposure to ophthalmic nonsteroidal anti-inflammatory drugs”. Clinical Ophthalmology 5 (2011): 269-274.
- Maulvi FA., et al. “Drug Delivery A review on therapeutic contact lenses for ocular drug delivery”. 8 (2016): 3017-3026.
- Netto MV., et al. “Censo Brasileiro de Cirurgia Refrativa”. Arquivos Brasileiros de Oftalmologia1 (2013): 29-32.
- Huhtala A., et al. “Femtosecond lasers for laser in situ keratomileusis: a systematic review and meta-analysis”. Clinical Ophthalmology 10 (2016): 393-404.
- Pallikaris IG., et al. “Laser in situ keratomileusis”. Lasers in Surgery and Medicine5 (1990): 463-468.
- Baker CM and Wong DL. “QUEST: A process of pain assessment in children”. Orthopaedic Nursing1 (1987): 11.20.
- Lim Li., et al. “Therapeutic Contact Lenses in the Treatment of Corneal and Ocular Surface Diseases—A Review”. Asia-Pacific Journal of Ophthalmology6 (2021): 524-532.
- Li CC and Chauhan A. “Modeling ofthalmic drug delivery by contact lens bundle”. Industrial and Engineering Chemistry Research 45 (2006): 3718-3734.
- Li CC and Chauhan A. “Ocular transport model for ophthalmic delivery of timolol through contact lenses p-HEMA”. Journal of Drug Delivery Science and Technology 17 (2007): 69-79.
- J Chauhan A. “Dexamethasone transport and ocular delivery from poly (hydroxyethyl methacrylate) gels”. International Journal of Pharmaceutics 353 (2008): 205-222.
- Dougherty PJ. “Acular LS before and during LASIK for the control of pain: a randomized, masked contralateral eye trial”. Journal of Refractive Surgery 25 (2009): 210-213.
- Cleaveland NA., et al. “Efficacy and perioperative timing of bromfenac in the management of ocular discomfort after femtosecond laser-assisted laser in situ keratomileusis”. Journal of Cataract and Refractive Surgery2 (2017): 183-188.
- Zhao LQ., et al. “Bandage Contact Lens Application Reduces Fibrotic Wound Healing of Flap Margins after FS-LASIK: A Prospective Randomized Clinical Trial”. Journal of Ophthalmology (2019): 1-10.
- Pahlitzsch T., et al. “LenSx®-Femto-LASIK, FEMTO LDV Z4®-Femto-LASIK und PRK: Vergleich refraktiver Ergebnisse und Komplikationsanalyse”. Der Ophthalmologe (2017): 115.